



14 NOVEMBER 2025
Hybrid Event

**Decentralized trials:
patient empowerment?**
Rebeca González Vicedo



Why Listen?



Rebeca González Vicedo

Director of Decentralized Client Solutions

*"Research must be aligned
with patients' reality"*

Experience

- ✓ Close to 10 years DCT experience building service from the ground up to covering Europe
- ✓ Worked on 100+ clinical trials with homecare visits

FutureMeds Site Solution

- ✓ 28 strategically located fully owned dedicated research sites in 7 countries in Europe
- ✓ Integrated site operations & inhouse QMS
- ✓ 330K+ prescreened patients in database*




- ✓ **Established homecare coverage in most European countries** (14K+ home visits delivered)
- ✓ **PI and site engagement expertise** (1850+ sites supported across 320+ projects)
- ✓ **Virtual FutureMeds PI + remote SI network**




Are we truly empowering patients—
or shifting responsibilities?

Clinical trials with decentralized elements



*Source: Globaldata, Retrieved on 16 October 2025



*Source: Globaldata, Retrieved on 16 October 2025

- Peak in 2021 addressing pandemic-related challenges, followed by a decline in studies incorporating DCT elements.
- 2025 anticipated to return to the level of 2021, reflecting a growing trend in the use of DCT solutions.
- Mobile Healthcare represent around 50% of DCT implementations and, together with digital adoption and remote patient monitoring, serve as key factors driving the market.

Small pockets of patients across the globe adding up to large, but difficult to engage, populations



20+ million
people live with
cancer worldwide

~8% in clinical trials¹



500+ million
people live with
CVDs worldwide

~5% in clinical trials²



300+ million
people live with
rare diseases worldwide

~16% in clinical trials³

How can we speed up the adoption of more effective trials in Europe?



Right Mindset

Address the misconceptions left behind by the let down of the pandemic hype



Right Focus

Engage patients where they are and collect real-world data reliably



Right Toolkit

Work to decide what elements should be decentralized to get the desired outcome

CASE STUDY

Duchenne Muscular Dystrophy

RARE DISEASE



Market context

- About 20,000 children are diagnosed with Duchenne globally each year¹ (Around 250,000 individuals worldwide)
- Despite the high unmet needs, recruiting for this indication is challenging and recruitment underperforms
- Between 2013-2022, Phase II trials under recruited by 23% on average, Phase III trials under recruited by 12% on average²
- Most patients are not mobile and families need flexible, reliable trial solutions that do not add additional burden

“Getting the research site visit experience right in the comfort of our home has been life-changing and gave us our family time back.”

Parent of a child enrolled in DMD trial

Trial Highlights

- ✓ Homevisits combined with site visits
- ✓ 14 patients - 2-6 years old children
- ✓ Ø 100 visits per patient , Ø 1 visit per week

Trial Activities

- ✓ Weekly IMP infusion
- ✓ 5-7 h visit duration with vital signs
- ✓ Sample collection, processing & shipment

2-6y

Patient's age

1400+

Total Visits

3+ Year

Study Duration

Decentralization ≠ automatic empowerment but with the right Decentralized elements used in trials we can...

Protect Clinical Trial Outcomes

- ✓ Protect trial timelines and mitigate costs
- ✓ Improve real-world data collection
- ✓ Provide more robust evidence for regulators

Revolutionize Patient Care

- ✓ Attract more & more diverse patients
- ✓ Increase patient population access to clinical research & improve their quality of life
- ✓ Increase global health equity

Increase Access to Cutting edge therapies

- ✓ Decrease cycle times
- ✓ Reduce numbers of unnecessary amendments
- ✓ Expedite product launch
- ✓ Increase ROI for all stakeholders

Design with patient, not just for them

Are we ready to listen before we implement?



Thank you for your
attention!

Rebeca.Gonzalez@futuremeds.com